Skip to content

ANAPANASATI MEDITATION TECHNIQUE FOR EFFECTIVE REDUCTION IN STRESS, ANXIETY & DEPRESSION: AN EXPERIMENTAL STUDY

Ashish Ubhale, Swati Raje

International Journal of Advanced Research January 31, 2022 DOI: 10.21474/ijar01/14022 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Pre-post intervention study Peer reviewed
Intervention Anapanasati meditation
Dose 10 minutes daily
Duration 4-week intervention
Measures Perceived Stress Scale (PSS), DASS-42
Topics Anxiety Depression Meditation
Key points A 10-minute daily Anapanasati meditation practice over four weeks significantly increased the number of participants without depression, anxiety, or stress.

Abstract

Stress is an integral part of human life and it can increase depression and anxiety which can hamper an individuals personal life, relationship or work satisfaction. To counter the issue of stress, anxiety and depression there are various pharmacological and nonpharmacological coping methods. As an intervention, the participants were taught Anapanasati meditation (brief mindfulness meditation) for 10 minutes daily for duration of 4 weeks (5 days a week). Self rating Perceived stress scale (PSS) and DASS-42 were administered before the beginning and at the end of the course. Analysis showed that the number of people who did not have depression, anxiety or stress increased significantly after the four weeks session of Anapana meditation. We conclude that even a very short span of 10 minutes of daily anapana meditation session can significantly and positively lower the intensity of depression, anxiety and stress.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Explore topics